GRENOBLE, France, June 30, 2015 /PRNewswire/ — The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to ImmunID's laboratory (Grenoble, France) based on results of a recent on-site inspection as part of the CAP's Accreditation Programs.
The facility's director, Jean-Francois Mouret, PharmD, was advised of this national recognition and congratulated for the excellence of the services being provided. ImmunID is one of more than 7,700 CAP-accredited facilities worldwide.
ImmunID's Chairman and Chief Executive Officer Bernhard Sixt said: "ImmunID's key policy is to adhere to the highest quality standards for the sake of patients and for a peace of mind for physicians. Hence we see our CAP accreditation as a logical step following our earlier ISO 13485 certification."
The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal-to or more-stringent-than the government's own inspection program.
During the CAP accreditation process, designed to ensure the highest standard of care for all laboratory patients, inspectors examine the laboratory's records and quality control of procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management.
About the College of American Pathologists
As the leading organization with more than 18,000 board-certified pathologists, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. The CAP's Laboratory Improvement Programs, initiated 65 years ago, currently have customers in more than 100 countries, accrediting 7,700 laboratories and providing proficiency testing to 20,000 laboratories worldwide.
Find more information about the CAP at cap.org. Follow CAP on Twitter: @pathologists
About ImmunID
ImmunID has been a pioneer in the immune molecular diagnostic field since 2005. Its two clinical products ImmunTraCkeR® and ImmunIG® evaluate a patient immune status based on T and B cell repertoire diversity, respectively. The company is establishing ImmunTraCkeR® as the general immune companion diagnostics for all immunotherapies and is setting the general immune molecular diagnostics standard globally. ImmunID collaborates with leading clinical research centers and biopharmaceutical companies worldwide to further validate ImmunTraCkeR® as an immune companion diagnostics for new immunotherapies and to widen clinical utility of its products. The company is ISO 9001 certified and runs an ISO 13485, CAP-accredited facility in the MINATEC high-tech campus in Grenoble, France.
www.immunid.com – Follow ImmunID on Twitter: @ImmunID
Contact
Bernhard Sixt
Chairman and CEO
Email
Phone: +33 438 785 770
Logo – http://photos.prnewswire.com/prnh/20150629/226677LOGO